{"analyses":[{"ciLowerLimit":"0.55","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.13","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.79","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"94.7","upperLimit":"99.2","value":"98.0"},{"groupId":"OG001","lowerLimit":"93.2","upperLimit":"98.6","value":"96.9"}]}],"title":"At Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.3","upperLimit":"98.6","value":"96.9"},{"groupId":"OG001","lowerLimit":"91.6","upperLimit":"97.8","value":"95.7"}]}],"title":"At Year 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.4","upperLimit":"97.8","value":"95.6"},{"groupId":"OG001","lowerLimit":"91.6","upperLimit":"97.8","value":"95.7"}]}],"title":"At Year 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.5","upperLimit":"96.5","value":"93.1"},{"groupId":"OG001","lowerLimit":"83.6","upperLimit":"95.2","value":"91.0"}]}],"title":"At Year 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"Cytogenetic response (CyR) is based on the prevalence of Philadelphia positive (Ph+) cells in metaphase from bone marrow (BM) sample. (Ideally, 25 metaphases but at least 20 metaphases from a BM sample were evaluated). Complete Cytogenetic Response (CCyR)=0% Ph+ cells in metaphase in BM. A cCCyR=those in which all measurements up to at least 28 days after the initial response show an equivalent or better CCyR.\n\nPercentage of participants in cCCyR at years 2, 3, 4 and 5 was computed for all randomized participants who achieved cCCyR as measured from the time of first confirmation until the date of progression or death. Participants with cCCyR who neither progress nor die are censored on the date of their last cytogenetic assessment. Participants without cCCyR are considered to have progressed on Day 1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tablets, oral, dasatinib 100 mg once daily (QD)","id":"OG000","title":"Dasatinib"},{"description":"Tablets, oral, imatinib 400 mg once daily (QD)","id":"OG001","title":"Imatinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants who achieved cCCyR","reportingStatus":"POSTED","timeFrame":"Years 2, 3, 4 and 5","title":"Percentage of Participants Remaining in Confirmed Complete Cytogenetic Response (cCCyR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}